The Plantrician Project’s Post

We have set our products and services related Academic Conference Archive.   Title: Dapagliflozin Alone or Combined with Ramipril Improves Hyperglycemia, Hypertension, and Prevents Kidney Complications and GFR Decline in the Nephrectomized SDT Fatty Rat Model of Diabetic Nephropathy.   Date: October 31 - November 1,2017   Info: Kidney Week 2017 (October 31 - November 1) ASN: Ernest N. Morial Convention Center, New Orleans, LA., USA   CLEA product: SDT fatty/Jcl   Keywords: Dapagliflozin、Ramipril、Glomerular Filtration Rate（GFR）、Hyperglycemia、Hypertension、obese、type 2 diabetic model   Please click here to see the detail. https://lnkd.in/gTi9i7Dh #Dapagliflozin #Ramipril #GlomerularFiltrationRate #Hyperglycemia #Hypertension #obese #type2diabeticmodel

The father of modern day weight loss medication 💊 Did you know Jens Juul Holst is in our scientific advisory board? 💎 Jens was the discoverer of GLP-1 and by many considered one of the leading experts globally on #obesity and #diabetes treatment, and the father of modern day medication for weight management! 🔎💡 In this clip, although a few years old, you can hear Jens discuss diabetes, its inflammatory process and how a TRPV-1 receptor antagonist like PILA PHARMA's could be of value! #PILA #Biotech #Cardiovascular #Diabetes #Obesity

GLP-1 receptor agonists, such as semaglutide and tirzepatide, are well-known for their role in weight management and glycemic control. These medications mimic the action of the endogenous GLP-1 hormone, which regulates appetite and insulin secretion. By activating GLP-1 receptors, these drugs not only aid in weight loss but also improve overall metabolic health and energy levels. GLP-1 therapy works by slowing gastric emptying, which helps maintain a feeling of fullness and reduces food intake. Additionally, it enhances glucose-dependent insulin secretion and suppresses glucagon release, leading to improved blood sugar control and reduced energy fluctuations throughout the day. Healthon offers personalized GLP-1 therapy to help you achieve your weight loss goals and boost your energy levels. By integrating this advanced treatment into your routine, you can experience sustained energy and improved metabolic function. Consult with Healthon’s experts to determine if GLP-1 therapy is right for you and to receive tailored guidance for maximizing its benefits. Sources: Aronne, L., et al. (2023). "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obseity." JAMA. 2024;331(1):38-48. doi:10.1001/jama.2023.24945 Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine, 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. #HealthGoals #GLP1 #WeightControl #HealthyWeight #DietAndExercise #MedicalTherapy #WeightLossJourney #WeightLossMotivation #GLP1WeightLoss #TelehealthWeightLoss #SustainableWeightLoss #WeightLossTransformation #WeightLossSupport #WeightLossTips #MedicalWeightLoss #FatLoss #ObesityManagement #WeightWatchers #FitnessJourney #HealthyLiving #GetFit #HealthyChoices #BodyTransformation #SlimDown #Ozempic #Semaglutide #Saxenda #Wegovy #Tirzepatide

Will be interesting to see next phase results

Published today: Lipoprotein Apheresis – Utility, Outcomes, and Implementation in Clinical Practice. http://spr.ly/6048Up8Sm Lipoprotein apheresis (LA) is a Food and Drug Administration (FDA) approved adjunctive therapeutic option for treating refractory high levels of low-density lipoprotein cholesterol (LDL-C) and lipoprotein (a), in children and adults with clinical heterozygous and homozygous familial hypercholesterolemia who meet the criteria. 📷: Lipoprotein apheresis: an overview of key concepts

"Emerging Role of Empagliflozin in Reshaping Diabetes Management" An insightful CME event was recently organized by Pakistan Society of Internal Medicine in collaboration with TABROS PHARMA (Pvt) Ltd. to delve into the emerging role of empagliflozin in transforming diabetes management. Discussion focused around latest clinical trials, research, and expert insights on how this innovative treatment is redefining the paradigm of glucose control and cardiovascular risk reduction. #drsomiaiqtadar #SciencewithSomia #diabetesmanagement

STAT reports on Novo Nordisk’s phase 1 trial of experimental oral medicine amycretin, with an average of 13.1% weight loss after 12 weeks. The weight loss is fast and large, in comparison to about 6% at the same time point for injectable medication Wegovy. Amycretin targets well-known GLP-1 as well as amylin – a hormone from the pancreas that reduces food intake by delayed stomach emptying, and well as decreasing blood glucose levels. A Phase II trial of the drug will commence in the second half of 2024, with results due in early 2026. https://lnkd.in/eGmjgnZq

Rounding out the morning in the CV track with Colleen Walsh-Irwin DNP, ANP-BC, AACC, EBP-C, FAANP giving a great overview of dyslipidemia medications. Key Takeaways: ✅️ Reducing LDL reduces CV risk and improves CV outcomes ✅️ Statin therapy is the foundation of management and additional agents should build on statins ✅️ Cholesterol can be targeted multiple ways: Intestinal absorption PCSK9 inhibiton Incrisilin ✅️ Clinical inertia in lipid management adds costs both monetarily and with increased morbidity/mortality ✅️ No such thing as a too-low LDL

🌟 World Arthritis Day: ECS Could Be a Game-Changer for Arthritis Management 🌟 October 12th is World Arthritis Day. Recent studies on the endocannabinoid system (ECS) reveal its potential in managing arthritis symptoms: 💡 Pain & Inflammation: ECS helps regulate these critical factors in arthritis. 🧬 Key Role: ECS influences joint health, cartilage integrity, and bone density. 🌿 Therapeutic Promise: CBD and other cannabinoids offer new avenues for relief. #WorldArthritisDay #ECSResearch #ArthritisRelief #CBD

ENROLLMENT COMPLETE: Our two Phase III clinical trials testing berberine ursodeoxycholate (HTD1801) in patients with type 2 #diabetes have completed enrollment. Both trials are evaluating our first-in-class gut-liver anti-inflammatory metabolic modulator for its effects on HbA1c and other indicators of glucose metabolism, lipids, markers of liver injury/function, and inflammation in patients with #T2DM; the first (SYMPHONY-1/NCT06350890) in patients who have poor glycemic control after dietary and exercise interventions, and the second (SYMPHONY-2/NCT06353347) in patients whose diabetes is inadequately controlled with metformin. Thank you to our team and all participants in these important studies. https://ow.ly/VlBV50SoYQ7 $2511HK #metabolicdisorders #pharma #clinicaltrials #drugdevelopment